The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxyfic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthatene-1-carboxylic acid (3-trifluoromethyI- phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1- carboxylic acid (3-trifluoromethyi-phenyi)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-πaphthalene-1- carboxyiic acid (3-trifluαromethyl-phenyl)-amide and to the manufacturing and use of such forms. The present invention also relates to a new process to produce 6-{6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.La présente invention concerne des compositions pharmaceutiques de (3-trifluorométhyl-phényl)-amide dacide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique, lutilisation de (3-trifluorométhyl-phényl)-amide dacide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique et des compositions de (3-trifluorométhyl-phényl)-amide dacide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique dans des applications thérapeutiques, en particulier des indications associées à une mauvaise régulation/surexpression de VEGF, une (néo)vascularisation et une angiogenèse dirigée par VEGF et des procédés de fabrication de ces compositions. Linvention concerne en outre des formes spécifiques de (3-trifluorométhyl-phényl)-amide dacide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique et la fabrication et lutilisation de ces formes. La présente invention concerne également un nouveau procédé pour produire du (3-trifluorométhyl-phényl)-amide dacide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-na
